Pharmafile Logo
Pharmafocus logo
Advanced Search

MS

Showing 15 posts of 92 posts found.

Vader image

Battle against prostate cancer gains celebrity endorsement

March 9, 2012
Medical Communications M&S, MS, Vader, prostate

A famous DJ and a legendary Star Wars actor have joined forces to raise awareness of prostate cancer. Star Wars …

News
Rebif image

Rebif approved for early use in MS

January 26, 2012
Sales and Marketing MS, Merck KGaA, Merck Serono, Rebif

The European Commission has approved an indication for multiple sclerosis treatment Rebif that treats early signs of the condition.This EC …

News

Biogen’s MS drug hits phase III targets

October 27, 2011
Sales and Marketing BG-12, Biogen, MS

Biogen’s potential blockbuster MS drug BG-12 has met its primary endpoint in a late-stage trial.   BG-12 (dimethyl fumarate) tablets …

News

MS audit finds little improvement in care

October 12, 2011
MS, multiple sclerosis

There has been “little or no improvement” in the care of multiple sclerosis patients over the past five years, according …

News

New MS drug shows promise for Abbott

August 10, 2011
Research and Development, Sales and Marketing Abbott, Avonex, Biogen, MS, gilenya

Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …

News
Gilenya

Gilenya rejected by NICE

August 5, 2011
Medical Communications, Sales and Marketing MS, NICE, Novartis, gilenya

NICE has not recommended Novartis’ multiple sclerosis drug Gilenya because of its cost and ‘uncertainties over its clinical effectiveness’. Gilenya …

News

Actelion’s MS candidate shows promise

August 2, 2011
Research and Development Actelion, MS

Actelion’s prospective multiple sclerosis pill ponesimod has cheered the company by meeting its primary endpoint in a phase IIb trial. …

News

Teva’s MS treatment disappoints

August 2, 2011
Research and Development, Sales and Marketing Laquinimod, MS, Teva

Teva and Active Biotech’s oral MS drug laquinimod has failed to meet its primary endpoint in a phase III trial. …

News

Bayer wields the axe at Emeryville plant

May 31, 2011
Manufacturing and Production Bayer, Emeryville, MS

Bayer Healthcare says it will cut 540 jobs at a production facility in Emeryville, California, next year after shifting production …

News
Novartis headquarters

First oral MS pill approved in Europe

March 21, 2011
Sales and Marketing MS, Novaris, fingolimod, first oral multiple sclerosis drug, gilenya, multiple sclerosis

Novartis’ Gilenya has become the first oral multiple sclerosis drug to be approved in Europe. Gilenya (fingolimod) is now licensed …

News
EMD Serono headquarters

FDA knocks back Merck KGaA’s oral MS drug

March 2, 2011
Sales and Marketing Cladribine, EMD Serono, FDA, MS, Merck KGaA, Movectro, multiple sclerosis, oral MS drugs

US authorities have turned down Merck KGaA’s new drug application for its oral relapsing-remitting multiple sclerosis treatment Movectro. The FDA …

News
Blog footer

Digital Pharma: Merck Serono sets up MS social network

February 18, 2011
Medical Communications Digital Pharma blog, MS, Merck Serono, Movectro, Rebif, multiple sclerosis, social networking

Merck Serono has set up an international social network for multiple sclerosis patients, saying today’s pharma companies should go beyond …

News
Merck Serono headquarters

Merck Serono halts Movectro European licence application

February 18, 2011
Medical Communications, Sales and Marketing Cladribine, MS, Merck KGaA, Merck Serono, Movectro, fingolimod, gilenya, multiple sclerosis

Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …

News

Novartis MS drug steals march over Merck rival

January 24, 2011
Sales and Marketing Cladribine, MS, Merck KGaA, Novartis, fingolimod, gilenya, multiple sclerosis

Novartis’ oral multiple sclerosis Gilenya could be on the European market in just three months after winning the backing of …

News

Roche highlights R&D promise after setbacks

December 9, 2010
Research and Development MS, Roche, oncology, personalised medicine, schizophrenia

Roche has presented its pipeline to shareholders to boost confidence that it can sustain the spectacular growth of recent years. …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025